Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLVSNASDAQ:SPPINASDAQ:VSTMNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLVSClovis Oncology$0.43$0.08▼$3.32$11.60M0.248.88 million shs1.16 million shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVSTMVerastem$4.93-5.0%$6.70$2.10▼$9.10$270.90M0.851.19 million shs7.28 million shsXOMAXOMA Royalty$24.05-2.3%$24.36$18.35▼$35.00$287.81M0.9432,853 shs142,227 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLVSClovis Oncology0.00%0.00%0.00%0.00%0.00%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem0.00%-11.96%-34.09%-25.86%+50.76%XOMAXOMA Royalty0.00%+0.84%-4.22%+15.18%+7.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLVSClovis OncologyN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum Pharmaceuticals0.4962 of 5 stars0.00.00.04.70.60.00.6VSTMVerastem2.5242 of 5 stars3.52.00.00.02.02.50.6XOMAXOMA Royalty3.9894 of 5 stars3.52.00.03.01.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLVSClovis Oncology 0.00N/AN/AN/ASPPISpectrum Pharmaceuticals 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.63176.37% UpsideXOMAXOMA Royalty 3.00Buy$69.50188.98% UpsideCurrent Analyst Ratings BreakdownLatest SPPI, CLVS, VSTM, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.004/17/2025XOMAXOMA RoyaltyBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.003/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLVSClovis Oncology$148.76M0.00N/AN/A($2.15) per share0.00SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87VSTMVerastem$10K27,090.35N/AN/A($0.65) per share-7.58XOMAXOMA Royalty$28.49M10.10N/AN/A$6.95 per share3.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLVSClovis Oncology-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AVSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)Latest SPPI, CLVS, VSTM, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/13/2025Q1 2025XOMAXOMA Royalty-$0.26$0.06+$0.32$0.06$6.75 million$15.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLVSClovis OncologyN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLVSClovis OncologyN/A0.140.12SPPISpectrum PharmaceuticalsN/A2.712.38VSTMVerastem2.773.503.50XOMAXOMA Royalty1.185.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLVSClovis Oncology24.53%SPPISpectrum Pharmaceuticals21.67%VSTMVerastem88.37%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipCLVSClovis Oncology4.40%SPPISpectrum Pharmaceuticals2.70%VSTMVerastem2.10%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLVSClovis OncologyN/A144.96 million138.58 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableSPPI, CLVS, VSTM, and XOMA HeadlinesRecent News About These CompaniesXOMA Preferred Shares Series A declares $0.539 dividendJune 18, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 18, 2025 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | investing.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | globenewswire.comXOMA (NASDAQ:XOMA) Upgraded by Wall Street Zen to "Buy" RatingJune 15, 2025 | americanbankingnews.comXOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street ZenJune 14, 2025 | marketbeat.comXOMA (NASDAQ:XOMA) Stock Rating Upgraded by Wall Street ZenJune 2, 2025 | marketbeat.comHC Wainwright Issues Positive Outlook for XOMA EarningsMay 31, 2025 | marketbeat.comPositive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy RatingMay 29, 2025 | tipranks.comXOMA's (XOMA) "Buy" Rating Reaffirmed at HC WainwrightMay 29, 2025 | marketbeat.comXOMA boosts stake in anti-CD38 antibody with $30 million dealMay 28, 2025 | thepharmaletter.comXOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 28, 2025 | benzinga.comXOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy RatingMay 28, 2025 | tipranks.comXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 MillionMay 27, 2025 | globenewswire.comWoodline Partners LP Acquires 60,927 Shares of XOMA Co. (NASDAQ:XOMA)May 27, 2025 | marketbeat.comInsider Selling: XOMA Co. (NASDAQ:XOMA) CEO Sells 25,637 Shares of StockMay 22, 2025 | insidertrades.comBvf Partners L. P/Il Sells 392,723 Shares of XOMA Co. (NASDAQ:XOMA) StockMay 21, 2025 | insidertrades.comMajor Shareholder Sells Massive Chunk of Xoma Stock!May 20, 2025 | tipranks.comXOMA Royalty First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | finance.yahoo.comXOMA Royalty Reports Strong Q1 2025 ResultsMay 14, 2025 | tipranks.comXOMA Royalty: Q1 Earnings SnapshotMay 13, 2025 | sfgate.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPPI, CLVS, VSTM, and XOMA Company DescriptionsClovis Oncology NASDAQ:CLVSClovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Verastem NASDAQ:VSTM$4.93 -0.26 (-5.01%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.09 +0.16 (+3.33%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XOMA Royalty NASDAQ:XOMA$24.05 -0.57 (-2.32%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$23.94 -0.12 (-0.48%) As of 06/20/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
